Business
Marina Biotech to Participate in the 29th Annual ROTH Conference
Marina Biotech to Participate in the 29th Annual ROTH Conference.
About this update from Adhera Therapeutics Inc.
[{"type":"text","content":"\n \n \n Marina Biotech to Participate in the 29th Annual ROTH Conference\n \n \nMarina Biotech to Participate in the 29th Annual ROTH Conference\n \n CITY OF INDUSTRY, CA--(Marketwired - Mar 1, 2017) - Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, has been invited to present at the 29th Annual ROTH Conference to be held at The Ritz-Carlton, Laguna Niguel in Dana Point, CA. \n Joseph Ramelli, Chief Executive Officer of Marina Biotech, is schedule to present on Wednesday, March 15, 2017 at 11:30 am PT. \n Mr. Ramelli will be joined by Dr. Vuong Trieu, the company's Chairman of the Board, for one-on-one meetings with investors. Investors attending the conference that wish to meet with Mr. Ramelli and Dr. Trieu for a one-on-one meeting should notify their appropriate contact at ROTH Capital Partners.\n For more information and registration, please visit the conference website by (clicking here). \n About Marina Biotech\n Marina Biotech is a biotechnology company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension, and cancer. Our pipeline includes combination therapies of oligonucleotide-based therapeutics and small molecules. The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome). By its merger with IthenaPharma, Marina Biotech recently acquired IT-102/IT-103 -- next generation celecoxib -- which will be developed together with CEQ508 as a therapeutic enhancer for therapies against FAP and CRC. IT-102/IT-103 are also being developed for the treatment of combined arthritis/ hypertension and treatment of pain requiring high dose of celecoxib. Additional information about Marina Biotech is available at http://www.marinabio.com.\n Forward-Looking Statements\n Statements made in this news release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking state...